More scientific support for mRNA-based coronavirus jabs in children

16 June 2022

Following Tuesday’s scientific recommendation to approve Moderna’s (Nasdaq: MRNA) coronavirus vaccine for older children, a panel of experts yesterday endorsed the jab for children as young as six months old.

The scientific advisors, which were drawn from academic backgrounds outside of the US Food and Drug Administration, also recommended the use of Pfizer (NYSE: PFE) and BioNTech’s (Nasdaq: BNTX) vaccine for this age group.

Moderna’s Spikevax jab is currently only authorized for use in adults in the USA, while Pfizer’s Comirnaty - by some way the leading coronavirus vaccine globally - is approved for older children already.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK